Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 126Radiotherapy 119Cisplatin 112Carboplatin 112pembrolizumab 110Nivolumab 106Docetaxel 91Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Fluorouracil 64Bevacizumab 64Oxaliplatin 63Etoposide 63Filgrastim 59Capecitabine 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 54Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × crenigacestat × Clear all
NCT02518113 2019-09-11

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Eli Lilly and Company

Phase 1/2 Completed
36 enrolled 17 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡